ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia

Interventions

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Gilteritinib

Given PO

DRUG

Venetoclax

Given PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER